Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,896 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06950307 | Hypofractionation for Prostate Cancer in Africa: A Feasibility Study(HypoAfrica) | active not recruiting | — | 182 | Muhimbili University of Health and Allied SciencesOTHER | 3 | Apr 30, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 |
| clinicaltrials |
| NCT03857477 | The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.(BARCODE1) | active not recruiting | — | 4,700 | Institute of Cancer Research, United KingdomOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06935487 | European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection(PCaVISTA) | active not recruiting | N/A | 806 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 6 | Apr 20, 2025 | clinicaltrials |
| NCT06458855 | Nerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy(PRP-NR) | active not recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06929884 | Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study | active not recruiting | — | 400 | Qianfoshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT01653093 | 3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer | active not recruiting | N/A | 280 | University of CincinnatiOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05608746 | Prehabilitation in Prostate Cancer Patients, TelePrehabTrial | active not recruiting | N/A | 40 | University of AarhusOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04302454 | Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy(ADOPT) | active not recruiting | Phase 3 | 280 | University Medical Center GroningenOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06850116 | Analysis of Immediate Urinary Continence Predictors After RS-RARP | active not recruiting | — | 400 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer(PATRON) | active not recruiting | Phase 3 | 800 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05523856 | New Treatment Modalities for Localized Prostate Cancer(TTOPROST/OBS) | active not recruiting | — | 480 | Fundacion IMIMOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT01492751 | Effectiveness of Localized Prostate Cancer Treatments(E-PROSTCaT) | active not recruiting | — | 500 | Fundacion IMIMOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03822494 | CyberKnife Dose Escalation Prostate Cancer Trial(CK-DESPOT) | active not recruiting | N/A | 100 | Crozer-Keystone Health SystemOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02302105 | Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer(POP-RT) | active not recruiting | N/A | 224 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06820502 | OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA | active not recruiting | N/A | 60 | Allama Iqbal Medical CollegeOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02446405 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer(ENZAMET) | active not recruiting | Phase 3 | 1,125 | University of SydneyOTHER | 6 | Feb 6, 2025 | clinicaltrials |
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone(PCS III) | active not recruiting | Phase 3 | 600 | Abdenour NabidOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT00223171 | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers(PCS IV) | active not recruiting | Phase 3 | 630 | Université de SherbrookeOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT05228197 | Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study.(IP6-CHAIROS) | active not recruiting | — | 750 | Imperial College LondonOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04009967 | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning(PICT-01) | active not recruiting | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT01444820 | Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate | active not recruiting | Phase 3 | 329 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT01583920 | Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer | active not recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02730338 | INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)(INTERVAL) | active not recruiting | N/A | 866 | Movember FoundationOTHER | 6 | Nov 27, 2024 | clinicaltrials |
| NCT03891732 | MRI Prostate for Chinese Men Being Screened for Prostate Cancer | active not recruiting | — | 690 | Chinese University of Hong KongOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02899312 | PSMA PET/CT for Assessment of Recurrent Prostate Cancer | active not recruiting | — | 2,244 | British Columbia Cancer AgencyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT05361902 | A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer(UPRATE) | active not recruiting | N/A | 35 | Erasmus Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2025source: clinicaltrials